Skip to content

PSP Research LLC 13F Holdings · Q3 2026

PSP Research LLC reported 44 securities worth $145.83M in its SEC 13F filing for Q3 2026 (period ended 2026-09-30). Top holdings: SGOV (48.33%), XBI (41.79%), SERA (3.43%). Among its top 25 positions this quarter: 1 new, 16 trimmed.

RankTickerCompanyValue% PortfolioSharesAction
1SGOVISHARES TR$70.5M48.33%700,000Hold
2XBISPDR SERIES TRUST$60.9M41.79%386,500Trimmed
3SERASERA PROGNOSTICS INC$5.0M3.43%2.4MNew
4HALOHALOZYME THERAPEUTICS INC$331,2000.23%3,000Trimmed
5MDGLMADRIGAL PHARMACEUTICALS INC$302,3760.21%600Hold
6ARGXARGENX SE$287,6730.20%300Trimmed
7EXELEXELIXIS INC$292,0500.20%5,000Trimmed
8NRIXNURIX THERAPEUTICS INC$284,5200.20%12,000Trimmed
9RPRXROYALTY PHARMA PLC$291,8000.20%5,000Trimmed
10HRMYHARMONY BIOSCIENCES HLDGS IN$274,8200.19%7,000Trimmed
11TARSTARSUS PHARMACEUTICALS INC$275,1350.19%3,500Trimmed
12TGTXTG THERAPEUTICS INC$278,9000.19%5,000Trimmed
13ARQTARCUTIS BIOTHERAPEUTICS INC$264,3000.18%10,000Trimmed
14IMNMIMMUNOME INC$258,1200.18%12,000Trimmed
15KNSAKINIKSA PHARMACEUTICALS INTL$261,1350.18%3,500Trimmed
16NBIXNEUROCRINE BIOSCIENCES INC$255,3120.18%1,800Trimmed
17SUPNSUPERNUS PHARMACEUTICALS$258,2400.18%6,000Hold
18ALKSALKERMES PLC$243,1200.17%6,000Hold
19AUPHAURINIA PHARMACEUTICALS INC$242,9250.17%15,000Trimmed
20DFTXDEFINIUM THERAPEUTICS INC$247,3900.17%6,500Trimmed
21INCYINCYTE CORP$242,7000.17%2,000Trimmed
22NTLAINTELLIA THERAPEUTICS INC$241,2000.17%20,000Hold
23ORKAORUKA THERAPEUTICS INC$249,8700.17%3,000Hold
24RVMDREVOLUTION MEDICINES INC$246,3120.17%1,200Hold
25TNGXTANGO THERAPEUTICS INC$249,5000.17%10,000Hold

Source: SEC Form 13F filings · as of 2026-09-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR